Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.
Michael S KellyJelena LewisHindu RaoJessica CarterIvan PortilloRichard BeuttlerPublished in: Pharmacotherapy (2022)
Pooled analysis of clinical trials reporting separate cardiovascular events rates in patients with T2DM and CKD did not find GLP1-RA to be associated with a reduction in composite cardiovascular event rates. Select GLP1-RA may offer cardiovascular event reduction in patients with T2DM and CKD, but this does not appear to be a class effect. Use of GLP1-RA with demonstrated cardiovascular benefits should be preferred in patients with CKD and T2DM to further reduce cardiovascular risk.
Keyphrases
- chronic kidney disease
- cardiovascular events
- end stage renal disease
- rheumatoid arthritis
- clinical trial
- disease activity
- coronary artery disease
- cardiovascular disease
- ankylosing spondylitis
- interstitial lung disease
- emergency department
- randomized controlled trial
- type diabetes
- systemic lupus erythematosus
- metabolic syndrome
- systemic sclerosis
- insulin resistance
- phase ii
- open label
- weight loss